Tafamidis treatment of transthyretin mediated amyloidosis (TTR) approved by FDA
Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals - Ein Podcast von Cleveland Clinic Heart & Vascular Institute - Donnerstags
Mazen Hanna, MD, Co-Director of the Cleveland Clinic’s Amyloidosis Center talks about the FDA’s recent approval of the drug Tafamidis for the treatment of ATTR Amyloidosis (also known as Amyloid Transthyretin Amyloidosis), the research behind it, what this medication does, and what this means for patients.
